E-Qure Corp

Absci Ai Research Lab is a generative AI drug creation company based in New York, NY. They are dedicated to creating better biologics for patients at a faster pace by designing antibodies from scratch using their zero-shot AI approach. Their breakthrough technology combines AI with synthetic biology to overcome the limitations of traditional drug discovery, enabling them to build and test millions of AI designs every week and validate new biologic-based therapeutics in as little as six weeks. Absci's innovative platform has the potential to disrupt the biopharmaceutical industry, with collaborations and partnerships with leading companies such as Merck, AstraZeneca, EQRx, and Almirall. Their powerful data generation and AI protein engineering platform, coupled with their unique disease biology insights, is revolutionizing drug discovery and production, offering innovative and cost-effective treatment options for patients.Generated from the website

Cell Source, Inc. is a pioneering biotechnology company based in New York, focused on developing next-generation immunotherapy solutions that enable rejection-free organ transplantation and safe stem cell treatments. Utilizing their innovative Veto Cell protocols, the company addresses significant challenges in allogeneic transplantation, including donor matching, graft versus host disease, and life-threatening infections. Under the leadership of Professor Yair Reisner, a prominent figure in immunology, Cell Source is advancing therapeutic approaches for various conditions such as leukemia, organ transplants, and non-malignant diseases like type-1 diabetes and multiple sclerosis. With a commitment to improving patient outcomes and quality of life, the company has achieved notable milestones, including the First In Human status for its Veto Cells in September 2019, and is currently conducting a Phase I/II clinical trial. Generated from the website

Xalud Therapeutics is a clinical-stage biotechnology company based in New York, NY, that is dedicated to developing a non-viral plasmid DNA-delivered gene therapy platform to treat chronic inflammatory diseases by restoring balance in the immune system. Their lead candidate, XT-150, is a locally injectable gene therapy that expresses a modified version of interleukin-10 (IL-10v), a potent cytokine that regulates multiple inflammatory pathways. Xalud aims to transform the treatment of chronic inflammatory diseases by addressing the underlying cause of the disease and improving the lives of patients burdened by these conditions.Generated from the website